Prelude Income Quality from 2010 to 2026
| PRLD Stock | USD 2.23 0.01 0.45% |
Income Quality | First Reported 2010-12-31 | Previous Quarter 0.93 | Current Value 0.91 | Quarterly Volatility 0.05742357 |
Check Prelude Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Prelude Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.1 M, Interest Expense of 1.6 M or Selling General Administrative of 20.7 M, as well as many indicators such as Price To Sales Ratio of 11.0, Dividend Yield of 0.0 or PTB Ratio of 0.69. Prelude financial statements analysis is a perfect complement when working with Prelude Therapeutics Valuation or Volatility modules.
Prelude | Income Quality | Build AI portfolio with Prelude Stock |
Analyzing Prelude Therapeutics's Income Quality over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Income Quality has evolved provides context for assessing Prelude Therapeutics's current valuation and future prospects.
Latest Prelude Therapeutics' Income Quality Growth Pattern
Below is the plot of the Income Quality of Prelude Therapeutics over the last few years. It is an assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure. Prelude Therapeutics' Income Quality historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Prelude Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Income Quality | 10 Years Trend |
|
Income Quality |
| Timeline |
Prelude Income Quality Regression Statistics
| Arithmetic Mean | 0.86 | |
| Geometric Mean | 0.86 | |
| Coefficient Of Variation | 6.65 | |
| Mean Deviation | 0.04 | |
| Median | 0.88 | |
| Standard Deviation | 0.06 | |
| Sample Variance | 0 | |
| Range | 0.2056 | |
| R-Value | (0.22) | |
| Mean Square Error | 0 | |
| R-Squared | 0.05 | |
| Significance | 0.39 | |
| Slope | (0) | |
| Total Sum of Squares | 0.05 |
Prelude Income Quality History
About Prelude Therapeutics Financial Statements
Prelude Therapeutics stakeholders use historical fundamental indicators, such as Prelude Therapeutics' Income Quality, to determine how well the company is positioned to perform in the future. Although Prelude Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Prelude Therapeutics' assets and liabilities are reflected in the revenues and expenses on Prelude Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Prelude Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Income Quality | 0.93 | 0.91 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Prelude Therapeutics is a strong investment it is important to analyze Prelude Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Prelude Therapeutics' future performance. For an informed investment choice regarding Prelude Stock, refer to the following important reports:Check out the analysis of Prelude Therapeutics Correlation against competitors. For information on how to trade Prelude Stock refer to our How to Trade Prelude Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Will Biotechnology sector continue expanding? Could Prelude diversify its offerings? Factors like these will boost the valuation of Prelude Therapeutics. Anticipated expansion of Prelude directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Prelude Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.47) | Revenue Per Share | Quarterly Revenue Growth 1.167 | Return On Assets | Return On Equity |
The market value of Prelude Therapeutics is measured differently than its book value, which is the value of Prelude that is recorded on the company's balance sheet. Investors also form their own opinion of Prelude Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Prelude Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Prelude Therapeutics' market value can be influenced by many factors that don't directly affect Prelude Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Prelude Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Prelude Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Prelude Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.